JAMA/tukuz.com
Feb 7, 2026, 06:50
ACOG 2023 Guideline on Premenstrual Disorders – JAMA
JAMA shared a post on LinkedIn:
“JAMA Clinical Guidelines Synopsis: The 2023 American College of Obstetricians and Gynecologists guideline on the management of premenstrual disorders recommends selective serotonin reuptake inhibitors (SSRIs)—used intermittently or continuously—as effective for affective symptoms, with evidence supporting their use.
Combined oral contraceptive pills, particularly those containing drospirenone, and cognitive behavior therapy are also recommended.
Treatment selection should consider individual patient goals, presence of affective or physical symptoms, and need for contraception.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Feb 7, 2026, 07:06Join Us for Insights on Senescence and Renewal in Reproductive Health – SRI
-
Feb 7, 2026, 07:01Heghine Khachatryan: Addressing Pregnancy Risks in Women With Glanzmann Thrombasthenia
-
Feb 7, 2026, 05:44Chloe Tran: Egg Freezing: An Effective Tool or False Security?
-
Feb 7, 2026, 05:34SMFM26 Expands Educational Opportunities in Maternal-Fetal Medicine – The Society for Maternal-Fetal Medicine
-
Feb 5, 2026, 16:22Plamen Todorov: Microfluidics for IVF: From Science to Clinical Validation
-
Feb 5, 2026, 16:18Impact of Bushfire Exposure on ART Outcomes Explored – RBMO
-
Feb 5, 2026, 16:15Robert Cincotta: Fetal Vulnerability in Anti-Ro/SSA and Anti-La/SSB Antibody-Positive Pregnancies
-
Feb 5, 2026, 16:13Transforming Contraception and Oncofertility with AMH Insights – SSR
-
Feb 4, 2026, 00:43Join the 2026 Rising Stars Webinar On February 11 – SSR